Pluristem

PSTI NASDAQ
3.840
-0.070
-1.79%
Opening 12:21 08/21 EDT
Open
3.870
Prev Close
3.910
High
3.870
Low
3.810
Volume
16.54K
Avg Vol (3M)
68.97K
52 Week High
13.80
52 Week Low
3.240
% Turnover
0.11%
Market Cap
58.80M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Pluristem PSTI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
MORE >

Recently

Name
Price
%Change